ADRB2 and Parkinson disease: Moreover, stratifying PD patients based on biomarkers of mitochondrial dysfunction and dynamics dysfunction mitochondrial dysfunction and biomarkers, may help identify subpopulations most likely to benefit from β2AR agonist therapy, therefore resolving uncertainties regarding patient selection and treatment response.